Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Current Diabetes Reports
|
June 24, 2025
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes
Aye Khine, Zoe Quandt
JAMA Oncology
|
June 4, 2026
Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply
Zoe Quandt, Megan Othus, Elad Sharon
Molecular and Clinical Oncology
|
April 18, 2017
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer
Naomi Serling-Boyd, Zoe Quandt, Nazima Allaudeen
Cancer Immunology Research
|
December 5, 2018
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Arabella Young, Zoe Quandt, Jeffrey A Bluestone
Frontiers in Endocrinology
|
September 28, 2023
Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
Cristiane J Gomes-Lima, Wen Zhou, Zoe Quandt
The Lancet. Diabetes & Endocrinology
|
March 20, 2019
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome
Ana Luisa Perdigoto, Zoe Quandt, Mark Anderson, et al.
Cold Spring Harbor Perspectives in Medicine
|
July 22, 2024
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease
Zoe Quandt, Ana Perdigoto, Mark S Anderson, et al.
Journal of the Endocrine Society
|
September 23, 2020
Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus
Zoe Quandt, Catherine Coupe, Mark Anderson, et al.
Diabetes Care
|
January 20, 2026
Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes
Aye Khine, Srinath Sanda, Christine Torok, et al.
Cancers
|
May 11, 2024
Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study
Eva Duvalyan, Sam Brondfield, Robert J Rushakoff, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Current Diabetes Reports
|
June 24, 2025
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes
Aye Khine, Zoe Quandt
JAMA Oncology
|
June 4, 2026
Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply
Zoe Quandt, Megan Othus, Elad Sharon
Molecular and Clinical Oncology
|
April 18, 2017
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer
Naomi Serling-Boyd, Zoe Quandt, Nazima Allaudeen
Cancer Immunology Research
|
December 5, 2018
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Arabella Young, Zoe Quandt, Jeffrey A Bluestone
Frontiers in Endocrinology
|
September 28, 2023
Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
Cristiane J Gomes-Lima, Wen Zhou, Zoe Quandt
The Lancet. Diabetes & Endocrinology
|
March 20, 2019
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome
Ana Luisa Perdigoto, Zoe Quandt, Mark Anderson, et al.
Cold Spring Harbor Perspectives in Medicine
|
July 22, 2024
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease
Zoe Quandt, Ana Perdigoto, Mark S Anderson, et al.
Journal of the Endocrine Society
|
September 23, 2020
Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus
Zoe Quandt, Catherine Coupe, Mark Anderson, et al.
Diabetes Care
|
January 20, 2026
Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes
Aye Khine, Srinath Sanda, Christine Torok, et al.
Cancers
|
May 11, 2024
Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study
Eva Duvalyan, Sam Brondfield, Robert J Rushakoff, et al.
Page
of 5